PRA Health Sciences, Inc. (NASDAQ:PRAH) VP Linda Baddour sold 100,000 shares of PRA Health Sciences stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $7,485,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) traded down 0.71% on Wednesday, hitting $75.16. The stock had a trading volume of 792,478 shares. PRA Health Sciences, Inc. has a one year low of $48.42 and a one year high of $80.99. The company has a market capitalization of $4.71 billion, a P/E ratio of 48.52 and a beta of 0.45. The firm has a 50 day moving average price of $75.18 and a 200 day moving average price of $67.70.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the Zacks’ consensus estimate of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The firm had revenue of $457.90 million during the quarter, compared to the consensus estimate of $447.79 million. During the same quarter in the prior year, the company earned $0.63 EPS. PRA Health Sciences’s quarterly revenue was up .5% on a year-over-year basis. On average, equities research analysts predict that PRA Health Sciences, Inc. will post $3.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “PRA Health Sciences, Inc. (PRAH) VP Sells $7,485,000.00 in Stock” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/pra-health-sciences-inc-prah-vp-sells-7485000-00-in-stock/1496388.html.

Several hedge funds have recently added to or reduced their stakes in PRAH. First Bank & Trust boosted its stake in PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after buying an additional 52 shares in the last quarter. Renaissance Group LLC boosted its stake in PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after buying an additional 126 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in PRA Health Sciences by 0.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock worth $1,428,000 after buying an additional 140 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in PRA Health Sciences by 1.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after buying an additional 160 shares in the last quarter. Institutional investors and hedge funds own 96.76% of the company’s stock.

A number of research analysts have recently weighed in on PRAH shares. Zacks Investment Research downgraded PRA Health Sciences from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and set a $92.00 price target (up previously from $88.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Citigroup Inc. reiterated a “buy” rating and set a $93.00 price target (up previously from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Credit Suisse Group lifted their price target on PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Finally, Bank of America Corporation started coverage on PRA Health Sciences in a report on Monday, June 26th. They set a “buy” rating and a $89.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $80.25.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.